JAMES LEE to Cytochrome P-450 CYP2C19
This is a "connection" page, showing publications JAMES LEE has written about Cytochrome P-450 CYP2C19.
Connection Strength
1.330
-
Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary intervention. Pharmacogenomics. 2024; 25(7):293-298.
Score: 0.864
-
Rates of 30-Day and 90-Day Readmission Between Genotype-Optimal and Genotype-Suboptimal Antiplatelet Therapy Prescribing After Percutaneous Coronary Intervention. Am J Cardiol. 2023 09 01; 202:218-222.
Score: 0.203
-
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Clin Pharmacol Ther. 2021 03; 109(3):705-715.
Score: 0.167
-
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention. Clin Pharmacol Ther. 2023 03; 113(3):615-623.
Score: 0.049
-
CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. J Am Heart Assoc. 2022 02 15; 11(4):e024159.
Score: 0.046